MedTrace Gathered +100 Doctors and Scientists of Nuclear Medicine for the Company’s Symposium on the Future of ¹⁵O-Water

On October 17, 2022, MedTrace hosted a discussion on the future of ¹⁵O-water in conjunction with the 35^th annual congress of the European Association of Nuclear Medicine in Barcelona. The event was the first symposium held by the company and probably the world’s first symposium on ¹⁵O-water. It was held to spark further interest in ¹⁵O-water and involve participants in recent developments that are making ¹⁵O-water easier to utilize for clinical and research purposes.

“We were happy to see so many people interested in the future of ¹⁵O-water and thankful for our speakers sharing their research results and their conclusions on how ¹⁵O-water may impact PET and cardiology”, says Martin Stenfeldt, CEO and co-founder of MedTrace.

The symposium was opened by Mark Lubberink, Professor of molecular imaging physics at Uppsala University and Scientific Advisor to MedTrace. He shared a historical overview of ¹⁵O-water PET from 1951 up until today.

Ibrahim Danad, MD, Phd; Cardiologist at Amsterdam UMC followed and shared his recent findings on the clinical value of ¹⁵O-water PET imaging from a cardiology perspective.

Professor Morten Bøttcher, MD, PhD; Cardiologist at Gødstrup Hospital was the third speaker. He shared results from his clinical research in perfusion imaging from SPECT to PET.

And finally, Lars Christian Gormsen, Nuclear Medicine Physician at Aarhus University Hospital shared his preliminary results from his research on the clinical use of ¹⁵O-water PET MPI in a tertiary PET center.

Lars Christian Gormsen is also Site Principal Investigator of Aarhus University Hospital, the first trial site to scan a subject in MedTrace’s Rapid-Water-Flow Phase III clinical trial.

The scientific part of the symposium was rounded off by a Q&A moderated by Professor Jens Sörensen from Uppsala University and Clinical Advisor to MedTrace.

MedTrace completed the symposium with drinks and appetizers for all participants.